Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPN729MA Tablets for Erectile Dysfunction Phase 3 Trial
CTR20222332Phase 3Completed
- Sponsor
- Tianfang Pharmaceutical Co., Ltd.
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in erectile dysfunction (ED) comparing TPN729MA tablets with Placebo (TPN729MA tablets simulator) (2 arms). Primary endpoints: Change from baseline in IIEF-EF domain score at end of treatment, Change in proportion of successful penetration attempts (SEP2) during treatment vs run-in and 1 more. Started Oct 2022; status: completed.
02
Drugs
vigafirstat
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on CTR20222332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222332.